Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Emergent BioSolutions Wins $24 Million BARDA Contract for Anthrax Vaccine

Emergent BioSolutions Wins $24 Million BARDA Contract for Anthrax Vaccine

MT newswireMT newswire2026/09/01 12:17
08:17 AM EDT, 09/01/2026 (MT Newswires) -- Emergent BioSolutions (EBS) said Tuesday it won a contract modification worth about $24 million from Biomedical Advanced Research and Development Authority to supply Cyfendus anthrax vaccine for US preparedness efforts. The company said the vaccine was approved by the US Food and Drug Administration in 2023 for post-exposure prevention of anthrax in adults ages 18 to 65 when used with recommended antibiotics.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!